Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | FPR3 | P25089 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14809114 | 0.90 | CTSD (0.36) | CYP4F2CYP4A11CA14FPR3FPR2 | |
| SCHEMBL4144318 | 0.84 | NFKB1 (0.37) | CYP4F2CYP4A11HDAC1HDAC2HDAC6 | |
| SCHEMBL4137259 | 0.83 | PDK2 (0.32) | CYP4F2CYP4A11FPR3FPR2ASGR1 | |
| SCHEMBL15116573 | 0.83 | CYP4F2 (0.33) | CYP4F2CYP4A11FPR3FPR2ASGR1 | |
| SCHEMBL22113052 | 0.82 | ASGR1 (0.32) | CYP4F2CYP4A11FPR3FPR2ASGR1 | |
| SCHEMBL15125117 | 0.81 | ASGR1 (0.31) | CA14FPR3FPR2ASGR1HDAC1 | |
| SCHEMBL15113643 | 0.79 | CTSL (0.31) | FPR3FPR2ASGR1 | |
| SCHEMBL6628984 | 0.79 | CYP4F2 (0.47) | CYP4F2CYP4A11CA14FPR3FPR2 | |
| SCHEMBL31703654 | 0.76 | HDAC6 (0.33) | CA14FPR3FPR2ASGR1HDAC1 | |
| SCHEMBL20993458 | 0.75 | FPR3 (0.33) | CA14FPR3FPR2ASGR1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020120576-A1 | p38α AUTOPHOSPHORYLATION INHIBITORS | FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (ES) | 2020-06-18 | — | — | WO | disclosed |
| US-9434753-B2 | Modified creatine compounds | GENCIA CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-20150005258-A1 | Modified Creatine Compounds | Genci Corporation (US) | 2015-01-01 | — | — | US | disclosed |
| CN-103889993-A | Modified creatine compounds | GENCIA CORP | 2014-06-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005258-A1 | Modified Creatine Compounds | CKMT1A; CKMT1B, SLC25A20, ARG2 | CYP4F2 2281/4885CYP4A11 3225/4885CA14 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.